Treatment of Postural Orthostatic Tachycardia Syndrome With Medication: A Systematic Review

J Child Neurol. 2020 Dec;35(14):1004-1016. doi: 10.1177/0883073820948679. Epub 2020 Aug 24.

Abstract

Purpose: Postural orthostatic tachycardia syndrome has been recognized for decades, but treatment is largely based on anecdotal experience and expert opinion. Pharmacologic treatment is inconsistent and unstandardized. We did a systematic review to identify controlled studies from which informed treatment decisions can be made.

Method: Through a standard systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we identified all English-language studies of a medication treatment for postural orthostatic tachycardia syndrome that included a comparison or control group and followed outcomes for at least 1 week of treatment.

Results: A total of 626 studies were identified by the search criteria, and 8, involving a total of 499 patients, met the criteria. No studies were adequately similar to allow for meta-analysis. Of the identified 8 studies, 2 were randomized controlled trials and 4 had been subjected to peer review. In individual studies, there was some favorable effect with fludrocortisone, beta blockers, midodrine, and selective serotonin reuptake inhibitors.

Conclusion: There is a paucity of high-quality data about effectiveness of medication in the treatment of postural orthostatic tachycardia syndrome. Nonetheless, 2 randomized trials and 6 other reports show some favorable effects of medication.

Keywords: autonomic dysfunction; beta blocker; fludrocortisone; midodrine; orthostatic intolerance; outcomes; postural orthostatic tachycardia syndrome; systematic review.

Publication types

  • Research Support, Non-U.S. Gov't
  • Systematic Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Anti-Inflammatory Agents / therapeutic use*
  • Fludrocortisone / therapeutic use*
  • Humans
  • Postural Orthostatic Tachycardia Syndrome / drug therapy*
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*
  • Treatment Outcome

Substances

  • Adrenergic beta-Antagonists
  • Anti-Inflammatory Agents
  • Serotonin Uptake Inhibitors
  • Fludrocortisone